Nafamostat mesilate for anticoagulation in continuous renal replacement therapy

International Journal of Artificial Organs

Volumn 36, Issue 3, 2013, Pages 208-216

  Hwang, Seun Deuk ^a   Hyun, Yu Kyung ^a   Moon, Sung Jin ^a   Lee, Sang Choel ^a   Yoon, Soo Young ^a  

^a Kwandong University College of Medicine   (South Korea)

Author keywords

Anticoagulation; Continuous renal replacement therapy; Nafamostat mesilate

Indexed keywords

AMINO ACIDS; MEDIAN FILTERS; PATIENT MONITORING; PATIENT TREATMENT; POLYSACCHARIDES;

AND FILTERS; ANTI-COAGULATION; CONTINUOUS RENAL REPLACEMENT THERAPY; EXTRACORPOREAL CIRCUITS; LIFESPANS; MEDIAN-FILTER; MEDICAL RECORD; NAFAMOSTAT MESILATE; RENAL REPLACEMENT THERAPIES; SERINE PROTEASE INHIBITOR;

INTENSIVE CARE UNITS;

CREATININE; HEPARIN; NAFAMSTAT MESILATE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANTICOAGULATION; APACHE; BLEEDING; BLOOD FLOW VELOCITY; BRAIN INFARCTION; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTINUOUS RENAL REPLACEMENT THERAPY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LIFESPAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; RETROSPECTIVE STUDY; REVIEW; SIMPLIFIED ACUTE PHYSIOLOGY SCORE; UREA NITROGEN BLOOD LEVEL;

EID: 84875644463     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.5301/ijao.5000191     Document Type: Review

References (37)

1. Mehta RL, Pascual MT, Gruta CG, Zhuang S, Chertow GM. Refining predictive models in critically ill patients with acute renal failure. J Am Soc Nephrol. 2002;13(5):1350-1357.
2. Uchino S, Kellum JA, Bellomo R, et al. Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005;294(7):813-818.
3. Ostermann M, Chang RW. Acute kidney injury in the intensive care unit according to RIFLE. Crit Care Med. 2007; 35(8):1837-1843, quiz 1852.
4. Metnitz PG, Krenn CG, Steltzer H, et al. Effect of acute renal failure requiring renal replacement therapy on out-come in critically ill patients. Crit Care Med. 2002;30(9): 2051-2058.
5. Abosaif NY, Tolba YA, Heap M, Russell J and El Nahas AM. The outcome of acute renal failure in the intensive care unit according to RIFLE: model application, sensitivity, and predictability. Am J Kidney Dis. 2005;46(6):1038-1048.
6. Hoste EA, Clermont G, Kersten A, et al. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care. 2006;10(3):R73.
7. Uchino S, Bellomo R, Ronco C. Intermittent versus continuous renal replacement therapy in the ICU: impact on electrolyte and acid-base balance. Intensive Care Med. 2001;27(6):1037-1043.
8. Kruczynski K, Irvine-Bird K, Toffelmire EB, Morton AR. A comparison of continuous arteriovenous hemofiltration and intermittent hemodialysis in acute renal failure patients in the intensive care unit. ASAIO J. 1993;39(3): M778-M781.
9. Tolwani AJ, Wille KM. Anticoagulation for continuous renal replacement therapy. Semin Dial. 2009;22(2):141-145.
10. Martin PY, Chevrolet JC, Suter P, Favre H. Anticoagulation in patients treated by continuous venovenous hemofiltration: a retrospective study. Am J Kidney Dis. 1994;24(5):806-812.
11. Kaplan AA, Longnecker RE, Folkert VW. Continuous arteriovenous hemofiltration. A report of six months' experience. Ann Intern Med. 1984;100(3):358-367.
12. Samuelsson O, Amiral J, Attman PO, et al. Heparin-induced thrombocytopenia during continuous haemofiltration. Nephrol Dial Transplant. 1995;10(9):1768-1771.
13. Uchiba M, Okajima K, Abe H, Okabe H, Takatsuki K. Effect of nafamostat mesilate, a synthetic protease inhibitor, on tissue factor-factor VIIa complex activity. Thromb Res. 1994;74(2):155-161.
14. Hitomi Y, Ikari N, Fujii S. Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system. Haemostasis. 1985;15(3):164-168.
15. Maruyama Y, Yoshida H, Uchino S, et al. Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: a three-year retrospective cohort study. Int J Artif Organs. 2011;34(7):571-576.
16. Baek NN, Jang HR, Huh W, et al. The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding. Ren Fail. 2012;34(3): 279-285.
17. Bagshaw SM, Laupland KB, Boiteau PJ, Godinez-Luna T. Is regional citrate superior to systemic heparin anticoagulation for continuous renal replacement therapy? A prospective observational study in an adult regional critical care system. J Crit Care. 2005;20(2):155-161.
18. Wu MY, Hsu YH, Bai CH, Lin YF, Wu CH, Tam KW. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2012;59(6): 810-818.
19. Aoyama T, Ino Y, Ozeki M, et al. Pharmacological studies of FUT-175, nafamstat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments. Jpn J Pharmacol. 1984;35(3):203-227.
20. Fuse I, Higuchi W, Toba K, Aizawa Y. Inhibitory mechanism of human platelet aggregation by nafamostat mesilate. Platelets. 1999;10(4):212-218.
21. Pak K, Shirasu A, Okino K, et al. [Effectiveness of FUT-175, protease inhibitor, as an anticoagulant to hemodialysis]. Hinyokika Kiyo. 1988;34(6):1077-1081.
22. Matsuo T, Kario K, Nakao K, Yamada T, Matsuo M. Anticoagulation with nafamostat mesilate, a synthetic protease inhibitor, in hemodialysis patients with a bleeding risk. Haemostasis. 1993;23(3):135-141.
23. Akizawa T, Koshikawa S, Ota K, Kazama M, Mimura N, Hirasawa Y. Nafamostat mesilate: a regional anticoagulant for hemodialysis in patients at high risk for bleeding. Nephron. 1993;64(3):376-381.
24. Yang JW, Han BG, Kim BR, et al. Superior outcome of nafamostat mesilate as an anticoagulant in patients undergoing maintenance hemodialysis with intracerebral hemorrhage. Ren Fail. 2009;31(8):668-675.
25. Bambrah RK, Pham DC, Zaiden R, Vu H, Tai S. Heparin-induced thrombocytopenia. Clin Adv Hematol Oncol. 2011;9(8):594-599.
26. Cronin RE, Reilly RF. Unfractionated heparin for hemodialysis: still the best option. Semin Dial. 2010;23(5): 510-515.
27. Kramer L, Bauer E, Joukhadar C, et al. Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med. 2003;31(10):2450-2455.
28. Bakker AJ, Boerma EC, Keidel H, Kingma P, van der Voort PH. Detection of citrate overdose in critically ill patients on citrate-anticoagulated venovenous haemofiltration: use of ionised and total/ionised calcium. Clin Chem Lab Med. 2006;44(8):962-966.
29. Morgera S, Schneider M, Slowinski T, et al. A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid-base status. Crit Care Med. 2009;37(6):2018-2024.
30. Mariano F, Tedeschi L, Morselli M, Stella M, Triolo G. Normal citratemia and metabolic tolerance of citrate anticoagulation for hemodiafiltration in severe septic shock burn patients. Intensive Care Med. 2010;36(10):1735-1743.
31. Bellomo R, Teede H, Boyce N. Anticoagulant regimens in acute continuous hemodiafiltration: a comparative study. Intensive Care Med. 1993;19(6):329-332.
32. Panphanpho S, Naowapanich S, Ratanarat R. Use of saline flush to prevent filter clotting in continuous renal replacement therapy without anticoagulant. J Med Assoc Thai. 2011;94(Suppl 1):S105-S110.
33. Inagaki O, Nishian Y, Iwaki R, Nakagawa K, Takamitsu Y, Fujita Y. Adsorption of nafamostat mesilate by hemodialysis membranes. Artif Organs. 1992;16(6):553-558.
34. Muto S, Imai M, Asano Y. Mechanisms of hyperkalemia caused by nafamostat mesilate. Gen Pharmacol. 1995;26(8): 1627-1632.
35. Okada H, Moriwaki K, Nakamoto H, Sugahara S, Suzuki H. Positive skin reaction test in haemodialysis patients allergic to nafamostat mesilate. Nephrol Dial Transplant. 1998; 13(8):2166-2167.
36. Maruyama H, Miyakawa Y, Gejyo F, Arakawa M. Anaphylactoid reaction induced by nafamostat mesilate in a hemodialysis patient. Nephron. 1996;74(2):468-469.
37. Okada H, Suzuki H, Deguchi N, Saruta T. Agranulocytosis in a haemodialysed patient induced by a proteinase inhibitor, nafamostate mesilate. Nephrol Dial Transplant. 1992; 7(9):980.